Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A Abivax S.A. Filed by: Invus Global Management, LLC

August 13, 2026 10:55 AM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 4,249,759 Ordinary Shares, nominal value Euro 0.01 per share (the "Shares"), and 540,428 American Depositary Shares ("ADSs"), each of which ADS represents one Share of Abivax S.A. (the "Issuer").


SCHEDULE 13G




Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 4,249,759 Ordinary Shares, nominal value Euro 0.01 per share (the "Shares"), and 540,428 American Depositary Shares ("ADSs"), each of which ADS represents one Share of Abivax S.A. (the "Issuer").


SCHEDULE 13G




Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 4,249,759 Ordinary Shares, nominal value Euro 0.01 per share (the "Shares"), and 540,428 American Depositary Shares ("ADSs"), each of which ADS represents one Share of Abivax S.A. (the "Issuer").


SCHEDULE 13G




Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 4,249,759 Ordinary Shares, nominal value Euro 0.01 per share (the "Shares"), and 540,428 American Depositary Shares ("ADSs"), each of which ADS represents one Share of Abivax S.A. (the "Issuer").


SCHEDULE 13G




Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 35,572 American Depositary Shares ("ADSs"), each of which ADS represents one Ordinary Share, nominal value Euro 0.01 per share (the "Shares"), of Abivax S.A. (the "Issuer").


SCHEDULE 13G




Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 35,572 American Depositary Shares ("ADSs"), each of which ADS represents one Ordinary Share, nominal value Euro 0.01 per share (the "Shares"), of Abivax S.A. (the "Issuer").


SCHEDULE 13G




Comment for Type of Reporting Person: Avicenna Life Sci Master Fund LP holds an aggregate of 35,572 American Depositary Shares ("ADSs"), each of which ADS represents one Ordinary Share, nominal value Euro 0.01 per share (the "Shares"), of Abivax S.A. (the "Issuer").


SCHEDULE 13G




Comment for Type of Reporting Person: Invus Public Equities, L.P. holds an aggregate of 4,249,759 Ordinary Shares, nominal value Euro 0.01 per share (the "Shares"), and 540,428 American Depositary Shares ("ADSs"), and Avicenna Life Sci Master Fund LP holds an aggregate of 35,572 ADSs, each of which ADS represents one Share of Abivax S.A. (the "Issuer").


SCHEDULE 13G



Invus Public Equities, L.P.
Signature:/s/ Raymond Debbane
Name/Title:Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner
Date:08/13/2026
Invus Public Equities Advisors, LLC
Signature:/s/ Raymond Debbane
Name/Title:Raymond Debbane, President
Date:08/13/2026
Invus Global Management, LLC
Signature:/s/ Raymond Debbane
Name/Title:Raymond Debbane, President
Date:08/13/2026
Siren, L.L.C.
Signature:/s/ Raymond Debbane
Name/Title:Raymond Debbane, President
Date:08/13/2026
Avicenna Life Sci Master Fund LP
Signature:/s/ Raymond Debbane
Name/Title:Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner
Date:08/13/2026
Avicenna Life Sci Master GP LLC
Signature:/s/ Raymond Debbane
Name/Title:Raymond Debbane, Chief Executive Officer
Date:08/13/2026
Ulys, L.L.C.
Signature:/s/ Raymond Debbane
Name/Title:Raymond Debbane, President
Date:08/13/2026
Raymond Debbane
Signature:/s/ Raymond Debbane
Name/Title:Raymond Debbane
Date:08/13/2026

ATTACHMENTS / EXHIBITS

JOINT FILING AGREEMENT

Categories

SEC Filings